Biomarker ID | 1735 |
PMID | 30866497 |
Year | 2019 |
Biomarker | Methylation Status of FBXO30 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs No Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 197 patients with Prostate cancer along with 37 normal samples (27 adjacent normal and 9 Benign Prostatic Hyperplasia) samples are chosen for the study |
Senstivity | 70.7 % |
Specificity | 94.6% |
AUC | 0.8459 |
Accuracy | NA |
Level Of Significance | p < 0.001 |
Method Used | quantitative methylation specific PCR (qMSP) |
Clinical | No |
Remarks | Specificity fixed at 94.6%. Calculated sensitivity accordinly |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |